Many Americans not getting breast, cervical, colon cancer screenings
the ONA take:
According to a study published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, researchers have found that many Americans are not getting recommended screening tests for breast, cervical, and colon cancers.
Specifically, results showed that among adults in the age groups recommended for screening, approximately one in four women not up to date with breast cancer screening, one in five women were not up to date with cervical cancer screening, and two in five were not up to date with colon cancer screening.
Of note, colon cancer screening rates were stagnant from 2010 to 2013 and cervical cancer screening using the Pap test in women 21 to 65 years of age was lower in 2013 than in 2000. In addition, mammography screenings changed minimally from previous years.
"It is often difficult to get patients to comply with screening tests, especially when they are uninsured or underinsured," said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City. However, healthcare providers need to convince patients that early screening can improve outcomes.
Many Americans are not getting recommended screening tests for breast, cervical, and colon cancers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|